PMID- 24201868
OWN - NLM
STAT- MEDLINE
DCOM- 20140813
LR  - 20211021
IS  - 1476-5500 (Electronic)
IS  - 0929-1903 (Print)
IS  - 0929-1903 (Linking)
VI  - 20
IP  - 12
DP  - 2013 Dec
TI  - Highly efficient tumor transduction and antitumor efficacy in experimental human 
      malignant mesothelioma using replicating gibbon ape leukemia virus.
PG  - 671-7
LID - 10.1038/cgt.2013.67 [doi]
AB  - Retroviral replicating vectors (RRVs) have been shown to achieve efficient tumor 
      transduction and enhanced therapeutic benefit in a wide variety of cancer models. 
      Here we evaluated two different RRVs derived from amphotropic murine leukemia 
      virus (AMLV) and gibbon ape leukemia virus (GALV), in human malignant 
      mesothelioma cells. In vitro, both RRVs expressing the green fluorescent protein 
      gene efficiently replicated in most mesothelioma cell lines tested, but not in 
      normal mesothelial cells. Notably, in ACC-MESO-1 mesothelioma cells that were not 
      permissive for AMLV-RRV, the GALV-RRV could spread efficiently in culture and in 
      mice with subcutaneous xenografts by in vivo fluorescence imaging. Next, GALV-RRV 
      expressing the cytosine deaminase prodrug activator gene showed efficient killing 
      of ACC-MESO-1 cells in a prodrug 5-fluorocytosine dose-dependent manner, compared 
      with AMLV-RRV. GALV-RRV-mediated prodrug activator gene therapy achieved 
      significant inhibition of subcutaneous ACC-MESO-1 tumor growth in nude mice. 
      Quantitative reverse transcription PCR demonstrated that ACC-MESO-1 cells express 
      higher PiT-1 (GALV receptor) and lower PiT-2 (AMLV receptor) compared with normal 
      mesothelial cells and other mesothelioma cells, presumably accounting for the 
      distinctive finding that GALV-RRV replicates much more robustly than AMLV-RRV in 
      these cells. These data indicate the potential utility of GALV-RRV-mediated 
      prodrug activator gene therapy in the treatment of mesothelioma.
FAU - Kubo, S
AU  - Kubo S
AD  - Department of Genetics, Hyogo College of Medicine, Nishinomiya, Japan.
FAU - Takagi-Kimura, M
AU  - Takagi-Kimura M
AD  - Department of Genetics, Hyogo College of Medicine, Nishinomiya, Japan.
FAU - Logg, C R
AU  - Logg CR
AD  - Department of Medicine, David Geffen School of Medicine, University of California 
      Los Angeles, Los Angeles, CA, USA.
FAU - Kasahara, N
AU  - Kasahara N
AD  - Department of Medicine, David Geffen School of Medicine, University of California 
      Los Angeles, Los Angeles, CA, USA.
LA  - eng
GR  - P30 DK041301/DK/NIDDK NIH HHS/United States
GR  - R01 CA121258/CA/NCI NIH HHS/United States
GR  - P30 DK 41301/DK/NIDDK NIH HHS/United States
GR  - R01CA121258/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20131108
PL  - England
TA  - Cancer Gene Ther
JT  - Cancer gene therapy
JID - 9432230
RN  - 0 (Prodrugs)
RN  - EC 3.5.4.1 (Cytosine Deaminase)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cytosine Deaminase/genetics/metabolism
MH  - Disease Models, Animal
MH  - Female
MH  - Gene Expression
MH  - Gene Order
MH  - Genetic Therapy
MH  - Genetic Vectors/administration & dosage/*genetics
MH  - Humans
MH  - Leukemia Virus, Gibbon Ape/*genetics
MH  - Lung Neoplasms/*genetics/metabolism
MH  - Mesothelioma/*genetics/metabolism
MH  - Mesothelioma, Malignant
MH  - Mice
MH  - Prodrugs
MH  - *Transduction, Genetic
MH  - Virus Replication
MH  - Xenograft Model Antitumor Assays
PMC - PMC8185610
MID - NIHMS1710119
COIS- CONFLICT OF INTEREST CRL and NK are paid consultants to Tocagen Inc.
EDAT- 2013/11/10 06:00
MHDA- 2014/08/15 06:00
PMCR- 2021/06/08
CRDT- 2013/11/09 06:00
PHST- 2013/08/25 00:00 [received]
PHST- 2013/10/17 00:00 [accepted]
PHST- 2013/11/09 06:00 [entrez]
PHST- 2013/11/10 06:00 [pubmed]
PHST- 2014/08/15 06:00 [medline]
PHST- 2021/06/08 00:00 [pmc-release]
AID - cgt201367 [pii]
AID - 10.1038/cgt.2013.67 [doi]
PST - ppublish
SO  - Cancer Gene Ther. 2013 Dec;20(12):671-7. doi: 10.1038/cgt.2013.67. Epub 2013 Nov 
      8.